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Strengths and limitations of this study
 ► This is the first comprehensive synthesis of evidence 
on the potential for overdiagnosis and overtreatment 
of attention deficit hyperactivity disorder in children 
and adolescents.
 ► Broad and systematic search strategy is used to re-
trieve all relevant studies published since 1979.
 ► The review compares evidence against estab-
lished criteria for potential overdiagnosis and 
overtreatment.
 ► The review includes a critical appraisal of included 
studies but no formal risk of bias assessment.
 ► Underdiagnosis and undertreatment may also occur, 
but are outside the scope of this review.
AbstrAct
Introduction Worldwide, attention deficit hyperactivity 
disorder (ADHD) diagnosis rates in children and 
adolescents have been increasing consistently over the 
past decades, fuelling a debate about the underlying 
reasons for this trend. While many hypothesise that 
a substantial number of these additional cases are 
overdiagnosed, to date there has been no comprehensive 
evaluation of evidence for or against this hypothesis. Thus, 
with this scoping review we aim to synthesise published 
evidence on the topic in order to investigate whether 
existing literature is consistent with the occurrence of 
overdiagnosis and/or overtreatment of ADHD in children 
and adolescents.
Methods and analysis The proposed scoping review 
will be conducted in the context of a framework of 
five questions, developed specifically to identify areas 
in medicine with the potential for overdiagnosis and 
overtreatment. The review will adhere to the Joanna Briggs 
Methodology for Scoping Reviews. We will search Medline, 
Embase, PsycINFO and the Cochrane Library electronic 
databases for primary studies published in English 
from 1979 onwards. We will also conduct forward and 
backward citation searches of included articles. Data from 
studies that meet our predefined exclusion and inclusion 
criteria will be charted into a standardised extraction 
template with results mapped to our predetermined five- 
question framework in the form of a table and summarised 
in narrative form.
Ethics and dissemination The proposed study is a 
scoping review of the existing literature and as such does 
not require ethics approval. We intend to disseminate 
the results from the scoping review through publication 
in a peer- reviewed journal and through conference 
presentations. Further, we will use the findings from 
our scoping review to inform future research to fill key 
evidence gaps identified by this review.
IntroduCtIon
review questions
Our primary study question for this scoping 
review is: ‘Does the published literature 
indicate a potential for overdiagnosis and/
or overtreatment of Attention Deficit Hyper-
activity Disorder (ADHD) in children and 
adolescents?’ Besides this question, we will 
consider two further, secondary questions 
in our review: ‘When mapped against an 
existing framework for identifying poten-
tial overdiagnosis,1 are there any gaps in the 
current evidence?’ and ‘How does the frame-
work1 perform in terms of applicability and 
usability for identifying potential overdiag-
nosis of a mental health condition?’
Background
With steadily increasing prevalence rates of 
ADHD throughout the developed world,2–6 
there is growing debate about whether this 
trend is due to an actual increase in preva-
lence, better detection and diagnosis, misdi-
agnosis, or overdiagnosis.7–10 While the 
evidence for overdiagnosis in many other 
conditions (especially in screen- detected 
cancers) is increasingly recognised,1 11 12 
the evidence for overdiagnosis of ADHD, a 
non- cancer condition where overdiagnosis 
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is widely thought to occur, has not yet been comprehen-
sively evaluated.13 Quantifying the potential for overdiag-
nosis is only just emerging as a field of interest in both 
paediatric and mental health research.7 14
The potential overdiagnosis of ADHD could be caused 
by three main drivers. First, it can arise due to the problem 
of overdefinition,15 that is, lowering the threshold for a 
disease, by expanding the disease definition to include 
people with ambiguous or very mild symptoms without 
evidence that doing so improves patients’ health overall 
and in the longer term.16 17 Second, overdiagnosis may 
also be caused by overdetection4 18 (eg, screening chil-
dren at young ages for behaviour problems), and third by 
the medicalisation of some behaviour patterns (eg, those 
typical of relatively younger school children).19 Other 
factors may also have played a part. These include formal 
changes to the diagnostic threshold (Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-5 vs DSM- 
IV), pharmaceutical industry influence,13 and health and 
social service drivers (eg, access to resources linked to a 
diagnosis).10
Although the prevalence rates of ADHD seem to 
have risen substantially in the past few years, most cases 
continue to be reported as mild to moderate forms (87% 
in 2007, 84% in 2011 and 86% in 2016 of all reported 
cases in a large USA- based survey),2 20 and it has been 
argued that many of those cases may represent overdi-
agnosis. Should this be the case, these children may not 
experience a net benefit from an ADHD diagnosis and 
subsequent treatments, but may be harmed.13
While correctly diagnosing and treating ADHD have 
many potential benefits,21 the harms from overdiag-
nosing and overtreating ADHD are significant and costly 
on multiple levels. Not only may the individual child 
experience negative physical and psychosocial effects, 
their families may also experience psychosocial and finan-
cial burdens. Overdiagnosis and overtreatment also result 
in financial and opportunity costs to the health system, 
and to society at large.7 It has also been pointed out that 
the resulting potential overuse of healthcare resources 
contributes to the simultaneous underuse of said 
resources,22 for example, by depriving underdiagnosed 
and undertreated groups of children who would largely 
benefit from ADHD treatment and timely access to diag-
nostic and treatment services.23 While also addressing 
the twin issues of underdiagnosis and undertreatment 
is beyond the scope of this proposed review, we see our 
work as a starting point for a broader discussion around 
the principles of ‘right care’, where resources need to be 
reallocated to where they are most needed and effective.22
rationale
In summary, while there are increasing concerns about 
the potential for overdiagnosis of ADHD in children 
and adolescents, there is scant evidence quantifying the 
problem. Consequently, a systematic review of the liter-
ature to quantify ADHD overdiagnosis is not possible 
due to the current lack of synthesisable evidence in this 
field. The rationale for this broader scoping review then 
is to use a recently developed framework of questions1 
to systematically determine if the existing literature indi-
cates a potential for overdiagnosis and overtreatment in 
ADHD. We hypothesise that ADHD fulfils these predeter-
mined criteria for potential overdiagnosis. A secondary 
aim is to further examine and highlight any gaps in the 
current evidence that may prevent us from determining 
whether or not ADHD is overdiagnosed and overtreated. 
This aim will be especially helpful in guiding subsequent 
research in this area. A further secondary aim of the study 
is to rigorously test the existing five- question framework1 
for its applicability and usability in another area, namely 
paediatric mental health.
Preliminary searches of the literature were conducted 
in March and April 2019 to determine if any previous 
scoping or systematic reviews had been conducted or 
protocols submitted which aimed to summarise existing 
evidence on overdiagnosis and overtreatment in ADHD. 
Databases searched were the Cochrane Database of 
Systematic Reviews, PROSPERO, Medline, Scopus and 
the JBI (Joanna Briggs Institute) Database of System-
atic Reviews and Implementation Reports. Two scoping 
reviews on overdiagnosis in healthcare were found, but 
neither review was focused on overdiagnosis and over-
treatment of ADHD. One review covered the drivers of 
overdiagnosis and potential solutions,22 while the other 
addressed overdiagnosis across different medical disci-
plines.24 25 While a number of systematic reviews have 
been conducted on ADHD, these have been restricted 
to prevalence26–28 or treatment options.29 30 We also 
identified one systematic review on overprescribing or 
underprescribing of ADHD medication that is currently 
under way with a published protocol.31 Literary reviews 
and commentaries on overdiagnosis in mental health, 
including ADHD, have been published.13 21 32 However, 
we found no reviews that have been conducted or are 
in preparation that systematically gather and analyse all 
available evidence to allow a comprehensive assessment 
on the potential for overdiagnosis of ADHD.
MEthodS and analySIS
The proposed review will follow the Joanna Briggs Meth-
odology for Scoping Reviews,33 which is based on and 
extends the work of Arksey and O’Malley34 as well as 
that of Levac and colleagues.35 The scoping review will 
also adhere to the Preferred Reporting Items for System-
atic Reviews and Meta- Analyses Extension for Scoping 
Reviews (PRISMA- ScR)36 (online supplement I). This 
approach was chosen to document the review process 
as clearly and rigorously as possible. The timeframe for 
undertaking of the review is from 13 June 2019 (date 
that the final search strategy was run in all included data-
bases) until 31 December (anticipated completion date 
of the review).
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Inclusion criteria
Participants
The scoping review will include studies whose main focus 
is on children and adolescents under the age of 18 who 
have been either clinically diagnosed or identified by the 
parent, teacher or self- report as having behavioural symp-
toms of ADHD. Articles that have a clear emphasis on 
adult ADHD will be excluded unless they are longitudinal 
follow- up studies where participants were determined to 
have ADHD in childhood and were then followed through 
into adulthood. Moreover, studies with other health issues 
or disabilities as the primary focus will also be excluded. 
However, studies considering any other comorbidities as 
a secondary diagnosis will be eligible for inclusion if the 
focus of the study is clearly on ADHD (outcomes on any 
other disorders will not be reported or included in the 
analysis).
Concept
The two core concepts to be examined by this scoping 
review are ‘overdiagnosis of ADHD’ and ‘overtreatment 
of ADHD’. Debate over the definition of overdiagnosis 
is ongoing,1 16 17 37 38 especially in non- cancer contexts. 
We define overdiagnosis as occurring where a person is 
correctly diagnosed (according to contemporary profes-
sional standards) with a condition but the net effect of the 
diagnosis for the individual concerned is unfavourable 
(ie, when consideration is given to the balance of poten-
tial harms and benefits).1 39 The resulting overtreatment 
can then be defined as receiving treatment following an 
overdiagnosis (or among overdiagnosed individuals).16 40 
It is important to note that overtreatment can occur as a 
result of overdiagnosis but also without it, due to other 
drivers.16 In this scoping review we will only consider 
pharmaceutical treatment options for ADHD in terms of 
overtreatment.
Context
The study will be conducted in the context of a previously 
published and tested framework of five questions that 
identify characteristics consistent with the occurrence 
of overdiagnosis and overtreatment.1 It is not limited to 
any geographical areas or settings. The five questions 
were developed by experts in the field of overdiagnosis 
as a guide to identifying areas in medicine where overdi-
agnosis and overtreatment may be occurring. Addition-
ally, an overarching primer question will be included to 
avoid missing evidence. Hence, the questions by which 
the search will be guided and to which the evidence will 
be mapped are the following:
0. Is ADHD overdiagnosed in children and adolescents?
1. Is there potential for increased diagnosis?
2. Is diagnosis actually increased?
3. Are additional cases subclinical or low risk?
4. Are additional cases treated?
5. Might harms outweigh benefits?
a. For treatment.
b. For diagnosis.
Types of evidence
For questions 0–4 any existing, peer- reviewed primary 
studies as well as systematic reviews will be considered. As 
our preliminary searches came up with very large amounts 
of evidence from primary studies that could be deemed 
suitable to answer question 5, we will limit the types of 
evidence included to answer this question as follows: the 
search for question 5 part A will be limited to systematic 
reviews (of randomised controlled trials or observational 
studies) and cohort studies investigating short- term and 
long- term outcomes from ADHD pharmaceutical treat-
ment. The search for question 5 part B will be wider and 
include any primary studies investigating outcomes after 
an ADHD diagnosis.
Search strategy
Initially, various basic, restricted searches in Medline 
and Scopus were performed on each of the five prede-
termined questions (1–5) to uncover some articles rele-
vant to the topic. This initial search was followed by an 
analysis of key concepts in titles and abstracts as well as 
index/medical subject heading terms from key papers. 
Moreover, we reviewed published search strategies from 
reviews on similar topics to identify keywords related to 
our study aims.24 25 A second full and complex search 
strategy with the identified keywords and index terms was 
then developed with the assistance of a research informa-
tion specialist. This search will be conducted in Medline, 
Embase, PsycINFO and the Cochrane Library to locate 
articles relevant to all five aspects of the framework and 
the additional primer question (0). For practical reasons 
this search will be restricted to English- language articles 
only. Databases will be searched from 1979 onwards. 
Publications from before 1979 will be excluded as their 
findings would reflect a historical definition of ADHD 
(hyperkinetic reaction of childhood) in line with DSM- 
II.41 These are unlikely to be relevant to our study ques-
tion. The complete search strategy for Medline can be 
found in online supplement II. Finally, the search will be 
supplemented by forward and backward citation searches 
of all included papers.
Study selection
After an initial pilot phase to ensure appropriate training 
for high- level decision making and to test our inclusion/
exclusion criteria, all titles and abstracts identified by the 
database and hand searches will be screened and reviewed 
for relevance by two researchers independently. Abstrackr 
(http:// abstrackr. cebm. brown. edu), a text mining tool, 
will be used to help with this initial screening.42 43 Full- 
text reviews of all potentially suitable papers will be inde-
pendently conducted by two researchers, according to 
the predefined inclusion/exclusion criteria. All studies 
excluded at the full- text screening stage will be reported 
with reasons for exclusion provided. At both stages of the 
screening process (abstract and full- text screening), any 
discrepancies will be resolved through discussion with the 
team.
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data extraction
Data from the final articles to be included in the review 
will be charted independently into a standardised and 
piloted template by two researchers. Any uncertainties 
will be again discussed and resolved by the entire study 
team. Data will be extracted on the source, eligibility, 
methods, population characteristics, intervention/expo-
sure, outcomes, results and other areas of interest. A 
template for data extraction is attached (online supple-
ment III) and may be further refined and updated during 
the review stage. As part of the data extraction process, 
all included studies will undergo a basic critical appraisal 
using the Joanna Briggs Institute Critical Appraisal Tools 
for the relevant study type (https:// joannabriggs. org/ 
critical_ appraisal_ tools).
Presentation of results
All information regarding the selection of sources will be 
presented in a flow diagram according to PRISMA- ScR.36
Results from all included studies will be mapped to 
our predetermined five- question framework in the form 
of a table as well as in descriptive, narrative form. This 
results table will include summary information from 
the conducted critical appraisals. Estimates from quan-
titative studies will be included in a summary table but 
will not be meta- analysed as we expect results to be too 
heterogeneous to allow for meaningful synthesis. Further, 
evidence will be categorised by type of article and study 
type in order to highlight where additional research may 
be needed to fill current evidence gaps.
Patient and public involvement
Neither the protocol nor the proposed scoping review 
will involve patients or members of the general public.
EthICS and dISSEMInatIon
Due to the proposed study being a scoping review, there 
are no ethical or safety considerations to be made. It is 
planned to disseminate the results from the scoping 
review through publication in a peer- reviewed journal 
and through conference presentations.
twitter Luise Kazda @@LuiseKazda, Katy Bell @KatyJLBell and Rae Thomas @
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